Draximage Mdp-25 25 mg (Medronic Acid POWDER FOR SOLUTION) 25 MG

DRAXIMAGE MDP-25 25 MG is a powder for solution used in medical imaging. This product, manufactured by Jubilant DraxImage Inc., is designed for intravenous administration and is commonly used in diagnostic procedures.

Strength

25 MG

Pack Size

10X10ML

Manufacturer / TM Owner

JUBILANT DRAXIMAGE INC. DBA JUBILANT RADIOPHARMA

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

DRAXIMAGE MDP-25 25 MG is primarily used in medical imaging to help visualize bone structures. It is often utilized in procedures to detect bone abnormalities or injuries. The powder is reconstituted into a solution and administered intravenously to assist in diagnostic imaging.

Side Effects

When administered, DRAXIMAGE MDP-25 25 MG works by binding to bone surfaces, which can be detected through imaging techniques. This process helps healthcare professionals identify areas of bone activity or irregularities. Common effects may include temporary discomfort at the injection site.

Precautions & Warnings

As with any medical product, it is important to follow the instructions provided by healthcare professionals. Ensure proper handling and storage to maintain the integrity of the powder. Always consult with a healthcare provider before use.

Avoid Interactions

DRAXIMAGE MDP-25 25 MG may interact with certain medications or substances. It is advisable to inform your healthcare provider about all medications you are taking to avoid potential interactions. Always follow the guidance of a medical professional.

Frequently Asked Questions

DRAXIMAGE MDP-25 25 MG is used in medical imaging to help visualize bone structures and detect abnormalities.

DRAXIMAGE MDP-25 25 MG is administered intravenously after being reconstituted into a solution.

Common effects may include temporary discomfort at the injection site.

Follow the instructions provided by healthcare professionals and ensure proper handling and storage.

It may interact with certain medications, so inform your healthcare provider about all medications you are taking.

Editorial & Trust Signals

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical wholesaler & exporter

Last updated: 17 Jun 2026

References

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.